EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Genomic characterization of multidrug-resistant extended-spectrum β-lactamase-producing Vibrio cholerae O1 strains from 2022 cholera outbreak in Kenya

Diana Imoli iD, John M Maingi, Cecilia Mbae, Susan M Kavai, Celestine Wairimu, Sheilla Mundalo, Georgina Odityo, Mary Wairimu, Zelalem Mekuria, Wondwossen Gebreyes, Samuel Kariuki iD

Journal of Antimicrobial Chemotherapy · 03.09.2025 · 80 (9) · 2399-2407

DOI: 10.1093/jac/dkaf224 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 14.07.2025. Verfasst von Diana Imoli und 10 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Microbiology Research, Kenya Medical Research Institute, Nairobi, Kenya. Hauptthemen laut MEDLINE: Vibrio cholerae O1, Cholera, Drug Resistance, Multiple, Bacterial, Disease Outbreaks. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, Wellcome and the Foreign, Commonwealth & Development Office.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In mid-2021, a global surge in cholera cases was reported. This study characterized Vibrio cholerae O1 isolates obtained from faecal samples of cholera-positive cases during the 2022 cholera outbreak in Kenya.

Methods

A total of 202 V. cholerae were confirmed through serogroup and serotype characterization by slide agglutination. Susceptibility testing was done using the Kirby–Bauer disc diffusion method, and ESBL production confirmed using the double-disc synergy test. WGS was performed on Illumina and ONT platforms, followed by bioinformatics analysis.

Results

All the isolates were identified as V. cholerae O1 of Ogawa serotype, with 99% classified as MDR and 98.5% positive for ESBL production. Notably, the isolates were resistant to azithromycin, one of the recommended antibiotics for cholera treatment. MDR was linked to the acquisition of an IncC plasmid (pVCMLK181) carrying seven resistance genes, including mph(A), mph(E) and msr(E), which confer resistance to azithromycin, and the blaPER-7 ESBL gene. Resistance to nalidixic acid was associated with mutations in QRDRs of gyrA and parC. The isolates also carried SXT/R391-like ICE, ICEVchInd5 featuring a 10 kb deletion and mapped to the 7PET-AFR13 lineage. Phylogenetic analysis revealed a close relationship to other highly drug-resistant AFR13 strains reported in Tanzania, Comoros and Mayotte.

Conclusions

The high prevalence of multidrug resistance in cholera isolates emphasizes the need for continuous surveillance to monitor the evolution of MDR V. cholerae O1 strains and calls for consideration of deployment of alternative management and prevention options including oral cholera vaccines and long-term improvement of water, sanitation and hygiene (WASH) infrastructure and practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Vibrio cholerae O1CholeraDrug Resistance, Multiple, BacterialDisease Outbreaksbeta-LactamasesKenyaHumansAnti-Bacterial AgentsMicrobial Sensitivity TestsWhole Genome SequencingSerogroupFecesGenome, BacterialPlasmids

Substanzen

beta-LactamasesAnti-Bacterial Agents

Autor:innen und Institutionen

  • Centre for Microbiology Research, Kenya Medical Research Institute, Nairobi, Kenya.
  • Department of Biochemistry, Microbiology and Biotechnology, Kenyatta University, Nairobi, Kenya.
  • Global One Health Initiative, Ohio State University, Columbus, OH, USA.
  • Parasites and Microbes Programme, Wellcome Sanger Institute, Cambridge, UK.
  • Drugs for Neglected Disease Initiative- Africa, Nairobi, Kenya.

ORCID-Profile: Diana Imoli, Samuel Kariuki

Förderung

  • Wellcome Trust
  • Wellcome and the Foreign, Commonwealth & Development Office

Zitieren

APA

Imoli, D., Maingi, J. M., Mbae, C., Kavai, S. M., Wairimu, C., Mundalo, S., Odityo, G., Wairimu, M., Mekuria, Z., Gebreyes, W., & Kariuki, S. (2025). Genomic characterization of multidrug-resistant extended-spectrum β-lactamase-producing Vibrio cholerae O1 strains from 2022 cholera outbreak in Kenya. Journal of Antimicrobial Chemotherapy, 80(9), 2399-2407. https://doi.org/10.1093/jac/dkaf224

Vancouver

Imoli D, Maingi JM, Mbae C, Kavai SM, Wairimu C, Mundalo S, et al. Genomic characterization of multidrug-resistant extended-spectrum β-lactamase-producing Vibrio cholerae O1 strains from 2022 cholera outbreak in Kenya. Journal of Antimicrobial Chemotherapy. 2025;80(9):2399-2407. doi:10.1093/jac/dkaf224

BibTeX
@article{Imoli2025,
  author = {Imoli, Diana and Maingi, John M and Mbae, Cecilia and Kavai, Susan M and Wairimu, Celestine and Mundalo, Sheilla and Odityo, Georgina and Wairimu, Mary and Mekuria, Zelalem and Gebreyes, Wondwossen and Kariuki, Samuel},
  title = {Genomic characterization of multidrug-resistant extended-spectrum β-lactamase-producing Vibrio cholerae O1 strains from 2022 cholera outbreak in Kenya},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2025},
  volume = {80},
  number = {9},
  pages = {2399--2407},
  doi = {10.1093/jac/dkaf224}
}
Kostenlos starten →